JP2017521370A5 - - Google Patents

Download PDF

Info

Publication number
JP2017521370A5
JP2017521370A5 JP2016569613A JP2016569613A JP2017521370A5 JP 2017521370 A5 JP2017521370 A5 JP 2017521370A5 JP 2016569613 A JP2016569613 A JP 2016569613A JP 2016569613 A JP2016569613 A JP 2016569613A JP 2017521370 A5 JP2017521370 A5 JP 2017521370A5
Authority
JP
Japan
Prior art keywords
concentration
preparation according
lyophilized
nr2b9c
tat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016569613A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017521370A (ja
JP6707469B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2015/053996 external-priority patent/WO2015181757A1/en
Publication of JP2017521370A publication Critical patent/JP2017521370A/ja
Publication of JP2017521370A5 publication Critical patent/JP2017521370A5/ja
Application granted granted Critical
Publication of JP6707469B2 publication Critical patent/JP6707469B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016569613A 2014-05-28 2015-05-28 アセチル化スカベンジャーを含むTat−NR2B9cの凍結乾燥製剤 Expired - Fee Related JP6707469B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462004144P 2014-05-28 2014-05-28
US62/004,144 2014-05-28
PCT/IB2015/053996 WO2015181757A1 (en) 2014-05-28 2015-05-28 Lyophilized formulation of tat-nr2b9c with acetylation scavenger

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020087977A Division JP2020143116A (ja) 2014-05-28 2020-05-20 アセチル化スカベンジャーを含むTat−NR2B9cの凍結乾燥製剤

Publications (3)

Publication Number Publication Date
JP2017521370A JP2017521370A (ja) 2017-08-03
JP2017521370A5 true JP2017521370A5 (enExample) 2018-06-21
JP6707469B2 JP6707469B2 (ja) 2020-06-10

Family

ID=54698211

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016569613A Expired - Fee Related JP6707469B2 (ja) 2014-05-28 2015-05-28 アセチル化スカベンジャーを含むTat−NR2B9cの凍結乾燥製剤
JP2020087977A Pending JP2020143116A (ja) 2014-05-28 2020-05-20 アセチル化スカベンジャーを含むTat−NR2B9cの凍結乾燥製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020087977A Pending JP2020143116A (ja) 2014-05-28 2020-05-20 アセチル化スカベンジャーを含むTat−NR2B9cの凍結乾燥製剤

Country Status (5)

Country Link
US (3) US10206878B2 (enExample)
EP (1) EP3148568A4 (enExample)
JP (2) JP6707469B2 (enExample)
CA (1) CA2950392A1 (enExample)
WO (1) WO2015181757A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10251935B2 (en) * 2012-11-28 2019-04-09 Nono Inc. Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose
ES2784500T3 (es) 2014-05-28 2020-09-28 Nono Inc Sal de cloruro de Tat-NR2B9c
CA2950392A1 (en) 2014-05-28 2015-12-03 Nono Inc. Lyophilized formulation of tat-nr2b9c with acetylation scavenger
EP4553432A1 (en) 2023-11-08 2025-05-14 Bachem Holding AG Drying bag and drying system
WO2025099273A1 (en) 2023-11-08 2025-05-15 Bachem Holding Ag Drying bag and drying system

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007212147A1 (en) * 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
MX2008012295A (es) * 2006-03-28 2008-10-09 Hoffmann La Roche Formulacion de un anticuerpo monoclonal humano anti-igf-1r.
EP1884521A1 (en) 2006-07-31 2008-02-06 Xigen S.A. Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
JP2012519712A (ja) * 2009-03-06 2012-08-30 メディミューン,エルエルシー ヒト化抗cd19抗体製剤
EP2458990B1 (en) * 2009-07-28 2016-03-30 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
NZ600096A (en) * 2009-11-20 2013-08-30 Centro Inmunologia Molecular Formulations of antibody
RU2588658C2 (ru) * 2010-04-27 2016-07-10 ЭсСиАйЭл Текнолоджи ГмбХ Стабильные водные композиции белка mia/cd-rap
EP2616094B1 (en) * 2010-08-12 2017-11-08 NoNO Inc. Treatment of penetrative injury to the brain
DK2709657T3 (en) * 2011-05-17 2019-01-14 Soligenix Inc Thermostable vaccine compositions and methods for their preparation
UY34105A (es) * 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
US10251935B2 (en) 2012-11-28 2019-04-09 Nono Inc. Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose
AU2013352437B2 (en) 2012-11-28 2018-04-12 Nono Inc. Lyophilized formulation of TAT-NR2B9c
CA2950392A1 (en) 2014-05-28 2015-12-03 Nono Inc. Lyophilized formulation of tat-nr2b9c with acetylation scavenger
ES2784500T3 (es) 2014-05-28 2020-09-28 Nono Inc Sal de cloruro de Tat-NR2B9c

Similar Documents

Publication Publication Date Title
JP2017521370A5 (enExample)
RU2016150678A (ru) ХЛОРИДНАЯ СОЛЬ ПЕПТИДА TAT-NR2B9с, КОМПОЗИЦИЯ НА ЕГО ОСНОВЕ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
JP2016520075A5 (enExample)
JP2015091902A5 (enExample)
ZA201900367B (en) Formulation of a peptide vaccine
WO2016184576A3 (en) Dry powder composition comprising long-chain rna
BR112017009405A2 (pt) composições antibióticas.
WO2015044337A3 (en) Dry formulations of vaccines that are room temperature stable
EA201890220A1 (ru) Вакцина против rsv
JP2013542919A5 (enExample)
PE20181400A1 (es) Formulacion farmaceutica acuosa del anticuerpo anti-pd-l1 avelumab
JP2014000092A5 (enExample)
PH12014501628A1 (en) Stabilized formulations containing anti-ang2 antibodies
WO2007035455A3 (en) Stabilizers for freeze-dried vaccines
PE20190420A1 (es) Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas
JP2018528242A5 (enExample)
HRP20191166T1 (hr) Stabilizirani proteini, namijenjeni imuniziranju protiv bakterije staphylococcus aureus
EP4606820A3 (en) Optimized ratios of amino acids and sugars as amorphous stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents
JP2017532343A5 (enExample)
AR082257A1 (es) Composicion de inmunoglobulinas humanas concentradas, procedimiento
HRP20211838T1 (hr) Krnji protein vp4 rotavirusa i njegova primjena
EA201491513A1 (ru) Рекомбинантные штаммы escherichia coli
EA202092926A2 (ru) Лиофилизированные составы, содержащие фактор ix
EA202090536A1 (ru) Кристаллические формы 3-замещенного 1,2,4-оксадиазола
EA201991023A1 (ru) Фармацевтическая композиция для парентерального введения, содержащая карглумовую кислоту